The short answer
Most BPC-157 research originates from a group at the University of Zagreb led by Predrag Sikirić, spanning three decades and covering gastrointestinal, musculoskeletal and vascular models. That concentration gives the literature depth and limits its independence.
Key facts
- Institution
- University of Zagreb
- Principal investigator
- Predrag Sikirić
- Span
- Roughly three decades
- Model organism
- Predominantly rat
- Range
- GI, tendon, ligament, vascular, ocular
- Clinical work
- PL-14736 for IBD
The scope of the programme
The Zagreb group has published on BPC-157 across an unusually wide range of models, gastrointestinal lesions, fistula healing, tendon and ligament repair, blood vessel effects, and more recently ocular applications. Sikirić's 2011 review in Current Pharmaceutical Design, 2020 work on fistula healing and 2023 paper in Pharmaceuticals map that breadth.
What sustained programmes provide
Continuity and accumulated method. A group that has worked on one molecule for thirty years knows its handling, its assays and its failure modes in ways that cannot be reconstructed from papers. That depth is valuable and it is why the Zagreb literature is the starting point for anyone studying this compound.
Research material referenced
BPC-157 5mg, third-party HPLC tested
The breadth question
A compound reported active in gastrointestinal, musculoskeletal, vascular and ocular models is either pleiotropic or is being tested by a group with a strong prior. Both are possible and they are not mutually exclusive. Breadth of reported activity is a reason for interest and also a reason for caution, because compounds that appear to work in everything have a poor historical record.
Why independent replication matters here specifically
Shared reagents, shared assays and shared assumptions propagate through a single group's output in ways that are invisible in any individual paper. Replication by unconnected investigators is what tests for that. For BPC-157 the independent literature is thinner than the total volume suggests, which is the single most useful caveat to carry into reading it.
The trial as an independence test
The Phase 2 trial now recruiting, NCT07437547, is sponsored by Hudson Biotech rather than by the original research group. A randomised, double-blind, placebo-controlled trial run by an unconnected sponsor is exactly the kind of test the literature has lacked, and its result (whichever way it goes) will be more informative than any further preclinical work.
Frequently asked questions
Who is Predrag Sikirić?
The researcher at the University of Zagreb who has led the BPC-157 research programme across roughly three decades and authored much of its literature.
Why does the current trial matter?
It is sponsored by an unconnected party and is randomised, double-blind and placebo-controlled. The independence test the literature has largely lacked.
Continue researching
Peer-reviewed guides, comparators and matched reference materials.
Primary sources & clinical trials
Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.
- PubMedSikiric P et al., Stable gastric pentadecapeptide BPC 157. Curr Pharm Des 2011 (PMID 21548867)pubmed.ncbi.nlm.nih.gov
- PubMedSikiric P et al., Fistulas Healing: BPC 157 Therapy. Curr Pharm Des 2020 (PMID 32329684)pubmed.ncbi.nlm.nih.gov
- PubMedSikiric P et al., BPC 157. Pharmaceuticals (Basel) 2023 (PMID 37513963)pubmed.ncbi.nlm.nih.gov
- TrialClinicalTrials.gov: BPC 157 Phase 2 (NCT07437547)clinicaltrials.gov
- PubMedKrivic A et al., Achilles detachment in rat and stable gastric pentadecapeptide BPC 157. J Orthop Res 2006 (PMID 16583442)pubmed.ncbi.nlm.nih.gov
- PubMedCerovecki T et al., Pentadecapeptide BPC 157 improves ligament healing in the rat. J Orthop Res 2010 (PMID 20225319)pubmed.ncbi.nlm.nih.gov
- PubMedSeiwerth S et al., BPC 157 and blood vessels. Curr Pharm Des 2014 (PMID 23782145)pubmed.ncbi.nlm.nih.gov
- PubChemPubChem · BPC-157 (CID 9941957)pubchem.ncbi.nlm.nih.gov
- GuidelineGoogle: Creating helpful, reliable, people-first contentdevelopers.google.com
Browse the wider literature
Live database searches, not fixed citations. Results change as new work is indexed.
Written and reviewed by
William Heath · Editor, UK Peptides research library
William Heath edits the UK Peptides research library. He is responsible for what is published here: every article is sourced to primary literature, every purity or identity statement traces to a signed third-party certificate for a specific lot, and corrections are made in place with the review date updated. No scientific or medical credentials are claimed on this site; the evidence is carried by the cited sources and the certificates, not by the byline.
More BPC-157 (Pentadecapeptide) articles
- BPC-157 CAS Number and Chemical IdentityCAS 137525-51-0, PubChem CID 9941957, 1419.5 Da. Unlike some research peptides, BPC-157's identifiers are unambiguous - and they check out.
- BPC-157 Molecular Weight: 1419.5 Da1419.5 Da for C62H98N16O22, verified against PubChem CID 9941957. Why this figure is stable across sources when others in the field are not.
- BPC-157 vs TB-500 ComparedDifferent origins, sizes, mechanisms and evidential positions. BPC-157 has registered clinical trials; TB-500's literature largely concerns its parent protein.
- BPC-157 Structure and SequenceGEPPPGKPADDAGLV: fifteen residues, four prolines, three glycines, no cysteine or methionine and no aromatic residue. What that composition implies.
- The Proline Problem in BPC-157 SynthesisFour prolines, three consecutive, make solid-phase synthesis meaningfully harder. Why proline coupling is a recognised difficult step, and what it costs purity.